1
|
Prischich D, Gomila AMJ, Milla‐Navarro S, Sangüesa G, Diez‐Alarcia R, Preda B, Matera C, Batlle M, Ramírez L, Giralt E, Hernando J, Guasch E, Meana JJ, Villa P, Gorostiza P. Adrenergic Modulation With Photochromic Ligands. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202010553] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/28/2022]
Affiliation(s)
- Davia Prischich
- Institute for Bioengineering of Catalonia (IBEC) The Barcelona Institute for Science and Technology (BIST) Barcelona Spain
- Centro de Investigación Biomédica en Red— Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) Spain
| | - Alexandre M. J. Gomila
- Institute for Bioengineering of Catalonia (IBEC) The Barcelona Institute for Science and Technology (BIST) Barcelona Spain
- Centro de Investigación Biomédica en Red— Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) Spain
| | | | - Gemma Sangüesa
- Institut Clínic Cardiovascular Hospital Clinic University of Barcelona (UB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Centro de Investigación Biomédica en Red— Enfermedades Cardiovasculares (CIBER-CV) Spain
| | - Rebeca Diez‐Alarcia
- Department of Pharmacology University of the Basque Country (UPV/EHU) Leioa Bizkaia Spain
- Centro de Investigación Biomédica en Red— Salud Mental (CIBER-SAM) Spain
| | - Beatrice Preda
- Institute for Bioengineering of Catalonia (IBEC) The Barcelona Institute for Science and Technology (BIST) Barcelona Spain
| | - Carlo Matera
- Institute for Bioengineering of Catalonia (IBEC) The Barcelona Institute for Science and Technology (BIST) Barcelona Spain
- Centro de Investigación Biomédica en Red— Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) Spain
| | - Montserrat Batlle
- Institut Clínic Cardiovascular Hospital Clinic University of Barcelona (UB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Centro de Investigación Biomédica en Red— Enfermedades Cardiovasculares (CIBER-CV) Spain
| | - Laura Ramírez
- Department of Systems Biology University of Alcalá (UAH) Madrid Spain
| | - Ernest Giralt
- Department of Inorganic and Organic Chemistry University of Barcelona (UB) Barcelona Spain
- Institute for Research in Biomedicine (IRB) Barcelona Institute for Science and Technology (BIST) Barcelona Spain
| | - Jordi Hernando
- Departament de Química Universitat Autònoma de Barcelona (UAB) Cerdanyola del Vallès Spain
| | - Eduard Guasch
- Institut Clínic Cardiovascular Hospital Clinic University of Barcelona (UB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Centro de Investigación Biomédica en Red— Enfermedades Cardiovasculares (CIBER-CV) Spain
| | - J. Javier Meana
- Department of Pharmacology University of the Basque Country (UPV/EHU) Leioa Bizkaia Spain
- Centro de Investigación Biomédica en Red— Salud Mental (CIBER-SAM) Spain
| | - Pedro Villa
- Department of Systems Biology University of Alcalá (UAH) Madrid Spain
- Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) Madrid Spain
| | - Pau Gorostiza
- Institute for Bioengineering of Catalonia (IBEC) The Barcelona Institute for Science and Technology (BIST) Barcelona Spain
- Centro de Investigación Biomédica en Red— Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) Spain
- Catalan Institution for Research and Advanced Studies (ICREA) Barcelona Spain
| |
Collapse
|
2
|
Prischich D, Gomila AMJ, Milla‐Navarro S, Sangüesa G, Diez‐Alarcia R, Preda B, Matera C, Batlle M, Ramírez L, Giralt E, Hernando J, Guasch E, Meana JJ, Villa P, Gorostiza P. Adrenergic Modulation With Photochromic Ligands. Angew Chem Int Ed Engl 2020; 60:3625-3631. [DOI: 10.1002/anie.202010553] [Citation(s) in RCA: 18] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/01/2020] [Revised: 09/21/2020] [Indexed: 12/30/2022]
Affiliation(s)
- Davia Prischich
- Institute for Bioengineering of Catalonia (IBEC) The Barcelona Institute for Science and Technology (BIST) Barcelona Spain
- Centro de Investigación Biomédica en Red— Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) Spain
| | - Alexandre M. J. Gomila
- Institute for Bioengineering of Catalonia (IBEC) The Barcelona Institute for Science and Technology (BIST) Barcelona Spain
- Centro de Investigación Biomédica en Red— Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) Spain
| | | | - Gemma Sangüesa
- Institut Clínic Cardiovascular Hospital Clinic University of Barcelona (UB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Centro de Investigación Biomédica en Red— Enfermedades Cardiovasculares (CIBER-CV) Spain
| | - Rebeca Diez‐Alarcia
- Department of Pharmacology University of the Basque Country (UPV/EHU) Leioa Bizkaia Spain
- Centro de Investigación Biomédica en Red— Salud Mental (CIBER-SAM) Spain
| | - Beatrice Preda
- Institute for Bioengineering of Catalonia (IBEC) The Barcelona Institute for Science and Technology (BIST) Barcelona Spain
| | - Carlo Matera
- Institute for Bioengineering of Catalonia (IBEC) The Barcelona Institute for Science and Technology (BIST) Barcelona Spain
- Centro de Investigación Biomédica en Red— Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) Spain
| | - Montserrat Batlle
- Institut Clínic Cardiovascular Hospital Clinic University of Barcelona (UB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Centro de Investigación Biomédica en Red— Enfermedades Cardiovasculares (CIBER-CV) Spain
| | - Laura Ramírez
- Department of Systems Biology University of Alcalá (UAH) Madrid Spain
| | - Ernest Giralt
- Department of Inorganic and Organic Chemistry University of Barcelona (UB) Barcelona Spain
- Institute for Research in Biomedicine (IRB) Barcelona Institute for Science and Technology (BIST) Barcelona Spain
| | - Jordi Hernando
- Departament de Química Universitat Autònoma de Barcelona (UAB) Cerdanyola del Vallès Spain
| | - Eduard Guasch
- Institut Clínic Cardiovascular Hospital Clinic University of Barcelona (UB), Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS) Barcelona Spain
- Centro de Investigación Biomédica en Red— Enfermedades Cardiovasculares (CIBER-CV) Spain
| | - J. Javier Meana
- Department of Pharmacology University of the Basque Country (UPV/EHU) Leioa Bizkaia Spain
- Centro de Investigación Biomédica en Red— Salud Mental (CIBER-SAM) Spain
| | - Pedro Villa
- Department of Systems Biology University of Alcalá (UAH) Madrid Spain
- Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) Madrid Spain
| | - Pau Gorostiza
- Institute for Bioengineering of Catalonia (IBEC) The Barcelona Institute for Science and Technology (BIST) Barcelona Spain
- Centro de Investigación Biomédica en Red— Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN) Spain
- Catalan Institution for Research and Advanced Studies (ICREA) Barcelona Spain
| |
Collapse
|
3
|
Uçan Gündüz G, Parmak Yener N, Kılınçel O, Gündüz C. How Does Usage of Serotonin Noradrenaline Reuptake Inhibitors Affect Intraocular Pressure in Depression Patients? J Ocul Pharmacol Ther 2018; 34:354-359. [PMID: 29446702 DOI: 10.1089/jop.2017.0133] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
PURPOSE To evaluate anterior segment parameters and intraocular pressure (IOP) modifications in patients using serotonin noradrenaline reuptake inhibitors (SNRIs) due to major depressive disorder. METHODS This cross-sectional study included 170 eyes of 85 subjects. All subjects were divided into three groups: group 1 included 44 healthy control subjects, group 2 included 22 patients receiving antidepressants for 1 week to 6 months, and group 3 included 19 patients receiving antidepressants for >6 months. All subjects underwent a detailed ophthalmologic examination, including gonioscopy. Anterior segments of all subjects were evaluated with the Scheimpflug system and pupil diameter (PD), central corneal thickness, anterior chamber depth (ACD), anterior chamber volume, and anterior chamber angle (ACA) measurements were enrolled. RESULTS The median IOP was significantly lower in patients using antidepressants [16.0 (11.0-21.0) mmHg] than the control group [17.5 (12.0-21.0) mmHg] (P = 0.041). The PD was significantly larger in patients using antidepressants [3.56 (2.29-5.60) mm] than the control group [2.95 (2.00-4.40) mm] (P = 0.000). In the study group, PD was also significantly larger in patients using SNRIs for ≥6 months [3.67 (2.38-5.08) mm] than <6 months [3.31 (2.29-5.60) mm] (P = 0.000). The median ACD was significantly lower in patients using antidepressants for ≥6 months [3.21 (2.52-4.06) mm] than the control group [3.44 (2.63-4.29) mm] (P = 0.000). ACAs were measured between 25° and 55° by Scheimpflug imaging. CONCLUSIONS Treatment of SNRIs causes mydriasis and decrease in width of ACD. These changes may not increase IOP as long as the patient has an open angle. SNRIs lead to decrease in IOP particularly in long-term usage.
Collapse
Affiliation(s)
- Gamze Uçan Gündüz
- 1 Department of Ophthalmology, Faculty of Medicine, Uludag University , Bursa, Turkey
| | - Neslihan Parmak Yener
- 2 Department of Ophthalmology, Yuksek Ihtisas Training and Research Hospital, University of Health Sciences , Bursa, Turkey
| | - Oğuzhan Kılınçel
- 3 Department of Psychiatry, Yenikent State Hospital , Sakarya, Turkey
| | - Cem Gündüz
- 4 Department of Psychiatry, Muammer Agım Gemlik State Hospital , Bursa, Turkey
| |
Collapse
|
4
|
Comparative pharmacodynamic analysis of imidazoline compounds using rat model of ocular mydriasis with a test of quantitative structure–activity relationships. J Pharm Biomed Anal 2017; 144:122-128. [DOI: 10.1016/j.jpba.2017.03.053] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2016] [Revised: 03/08/2017] [Accepted: 03/26/2017] [Indexed: 11/23/2022]
|
5
|
Raczak-Gutknecht J, Frąckowiak T, Nasal A, Kornicka A, Sączewski F, Kaliszan R. Are Alpha-2D Adrenoceptor Subtypes Involved in Rat Mydriasis Evoked by New Imidazoline Derivatives: Marsanidine and 7-Methylmarsanidine? Dose Response 2017; 15:1559325817701213. [PMID: 28491012 PMCID: PMC5405787 DOI: 10.1177/1559325817701213] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
The imidazoline compounds may produce mydriasis after systemic administration to some species (rats, cats, and mice). In mydriatic activity of imidazolines, α2D-adrenoceptors subtype(s) seems to be involved. In this study, the pupil dilatory effect evoked by 2 newly synthesized imidazoline derivatives—α2-adrenoceptor agonists: marsanidine and 7-methylmarsanidine—was compared. The compounds were tested alone as well as in the presence of α2-adrenoceptor antagonists (nonselective, yohimbine, and selective toward the following α2-adrenoceptor subtypes—α2A-2-[(4,5-dihydro-1H-imidazol-2-yl)methyl]-2,3-dihydro-1-methyl-1H-isoindole maleate (BRL44408), α2B-2-[2-(4-(2-methoxyphenyl)piperazin-1-yl)ethyl]-4,4-dimethyl-1,3-(2H,4H)-isoquinolindione dihydrochloride (ARC239), α2C-JP1302, α2D-2-(2,3-dihydro-2-methoxy-1,4-benzodioxin-2-yl)-4,5-dihydro-1H-imidazole hydrochloride [RX821002]). The agonists were studied in male Wistar rats and were administered intravenously in cumulative doses. The antagonistic compounds were given in a single dose before the experiment with marsanidine or 7-methylmarsanidine. Pupil diameter was measured with stereoscopic microscope equipped in green light filter. Marsanidine and 7-methylmarsanidine exerted marked mydriatic effects. BRL44408, JP1302, and ARC239 did not cause significant parallel shift to the right of the dose–effect curves obtained for both imidazolines. In case of yohimbine and RX821002, the marked parallel shifts of dose–response curves were observed, with the antagonistic effects of RX821002 more pronounced. In vivo pharmacodynamics experiment suggests that α2D-adrenoceptor subtype is mainly engaged in mydriatic effects evoked in rats by imidazoline derivatives, in particular by clonidine.
Collapse
Affiliation(s)
- Joanna Raczak-Gutknecht
- Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, Gdańsk, Poland
| | - Teresa Frąckowiak
- Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, Gdańsk, Poland
| | - Antoni Nasal
- Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, Gdańsk, Poland
- Antoni Nasal, Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland.
| | - Anita Kornicka
- Department of Chemical Technology of Drugs, Medical University of Gdańsk, Gdańsk, Poland
| | - Franciszek Sączewski
- Department of Chemical Technology of Drugs, Medical University of Gdańsk, Gdańsk, Poland
| | - Roman Kaliszan
- Department of Biopharmaceutics and Pharmacodynamics, Medical University of Gdańsk, Gdańsk, Poland
| |
Collapse
|
6
|
Kokot A, Zlatar M, Stupnisek M, Drmic D, Radic R, Vcev A, Seiwerth S, Sikiric P. NO system dependence of atropine-induced mydriasis and L-NAME- and L-arginine-induced miosis: Reversal by the pentadecapeptide BPC 157 in rats and guinea pigs. Eur J Pharmacol 2015; 771:211-9. [PMID: 26698393 DOI: 10.1016/j.ejphar.2015.12.016] [Citation(s) in RCA: 21] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2015] [Revised: 11/13/2015] [Accepted: 12/09/2015] [Indexed: 02/07/2023]
Abstract
We revealed an immediate and hours-lasting particular NO-specific parallel miotic effect of L-NAME and L-arginine in rats and guinea pigs and a stable gastric pentadecapeptide BPC 157 157-particular effect vs. that of atropine-induced mydriasis while examining the NO system role in the normal pupils responses and pupils with atropine-induced mydriasis. We also assessed the responses to BPC 157 and its possible modulation of the changes caused by L-NAME/L-arginine and atropine. We administered locally (two drops/eye) or systemically (intraperitoneally/kg) [BPC 157 (0.4µg/eye; 10µg, 10ng, 10pg/kg), L-NAME (0.1mg/eye; 5mg/kg), and L-arginine (2mg/eye; 100mg/kg) alone and combined] at 3min prior to assessment (normal pupils) or alternatively at maximal 1% atropine-induced mydriasis (30min after two drops were administered to each eye). L-NAME/L-arginine. Normal pupil. L-NAME-miosis and L-arginine-miosis shortened and attenuated each other's responses when combined (L-NAME+L-arginine) (except with guinea pigs treated locally) and were thereby NO-specific. Atropine-pupil. Both L-NAME and L-arginine counteracted atropine-induced mydriasis. With few exceptions, the atropine+L-NAME+L-arginine-animals showed a consistent shift toward the left. BPC 157. Normal pupil. Always, BPC 157 alone (both species; locally; systemically; all regimens) did not affect normal pupils. Despite specific exceptions, BPC 157 distinctively affects L-arginine-miosis (prolongation) and L-NAME-miosis (shortening). When L-arginine and L-NAME were combined (L-NAME+L-arginine+BPC 157), the effect was less pronounced. Atropine-pupil. BPC 157 alone counteracted atropine-induced mydriasis. With few exceptions (when administered with L-NAME or L-arginine or L-NAME+L-arginine), BPC 157 augments their counteracting effects. Thus, along with its l-NAME/L-arginine effects, BPC 157 participates in ocular control, potentially via NO-mediated and cholinergic mechanisms.
Collapse
Affiliation(s)
- Antonio Kokot
- Department of Anatomy and Neuroscience, Faculty of Medicine, J.J. Strossmayer University of Osijek, J.Huttlera 4, 31000 Osijek, Croatia
| | - Mirna Zlatar
- Department of Pharmacology, School of Medicine, University of Zagreb, POB 916, Salata 11, 10000 Zagreb, Croatia
| | - Mirjana Stupnisek
- Department of Pharmacology, Faculty of Medicine, J.J. Strossmayer University of Osijek, J.Huttlera 4, 31000 Osijek, Croatia
| | - Domagoj Drmic
- Department of Pharmacology, School of Medicine, University of Zagreb, POB 916, Salata 11, 10000 Zagreb, Croatia
| | - Radivoje Radic
- Department of Anatomy and Neuroscience, Faculty of Medicine, J.J. Strossmayer University of Osijek, J.Huttlera 4, 31000 Osijek, Croatia
| | - Aleksandar Vcev
- Department of Pharmacology, School of Medicine, University of Zagreb, POB 916, Salata 11, 10000 Zagreb, Croatia
| | - Sven Seiwerth
- Department of Pathology, School of Medicine, University of Zagreb, Salata 9, 10000 Zagreb, Croatia
| | - Predrag Sikiric
- Department of Pharmacology, School of Medicine, University of Zagreb, POB 916, Salata 11, 10000 Zagreb, Croatia.
| |
Collapse
|
7
|
Wróblewska M, Kasprzyk J, Sączewski F, Kornicka A, Boblewski K, Lehmann A, Rybczyńska A. Marsanidine and 7-Me-marsanidine, the new hypotensive imidazolines augment sodium and urine excretion in rats. Pharmacol Rep 2013; 65:1025-32. [DOI: 10.1016/s1734-1140(13)71085-5] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2012] [Revised: 03/18/2013] [Indexed: 11/26/2022]
|